Product Description
CMTX-101 is an immune-enabling antibody therapy with broad-spectrum activity that is in development for a first indication in moderate-to-severe pneumonia caused by Gram-positive or Gram-negative bacteria. (Sourced from: https://clarametyx.com/our-platform/)
Mechanisms of Action: Gram+ Bacteria Inhibitor, Gram- Bacteria Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: Fast Track - Cystic Fibrosis *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Clarametyx Biosciences
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Cystic Fibrosis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06159725 |
CMTX101-P1-CT002 | P2 |
Completed |
Cystic Fibrosis |
2025-11-14 |
12% |
2025-11-22 |
Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
10/20/2025 |
News Article |
Clarametyx Biosciences Strengthens Leadership Team to Accelerate Pipeline and Corporate Development Progress |
|
10/16/2025 |
News Article |
Clarametyx Biosciences Announces Completion of Enrollment in Phase 2a Study of CMTX-101 in Cystic Fibrosis |
|
08/04/2025 |
News Article |
Clarametyx Biosciences Announces FDA Grant of Fast Track and Qualified Infectious Disease Product Designations for CMTX-101 |
|
01/28/2025 |
News Article |
Clarametyx Biosciences Announces Investment by Kineticos AMR Accelerator Fund |